Photosensitivity associated with antipsychotics, antidepressants and anxiolytics.

Drug Saf

Unit of Photodynamic Therapy, Elisha Medical Center, Haifa, Israel.

Published: April 1996

Photosensitivity reactions evoked by systemic agents are the result of the effects of the agent combined with subsequent exposure to light. Photosensitivity induced by exogenous parenteral agents accounts for an increasing portion of the total undesirable effects caused by environmental chemicals. The exponential increase in the number of new drugs introduced each year may be one of the factors explaining the increased number of reports describing photosensitivity induced by exogenous agents. There are many reports of photosensitivity caused by antipsychotic and antidepressant agents. Although the majority of the research was focused on the photosensitising potential of chlorpromazine, other antipsychotics and antidepressants have been shown to cause cutaneous photosensitivity. An extensive drug history must be taken whenever a patient presents with a reaction limited to, or accentuated in, light-exposed areas. It should be remembered that these reactions may present with a wide morphological spectrum ranging from sunburn-like responses to eczematous, lichenoid and even bullous lesions, resembling porphyria cutanea tarda. In order to properly diagnose photosensitivity to systemic drugs it is important to prove photosensitivity by phototesting and to rule out other causes of systemic photosensitivity such as systemic lupus erythematosus and porphyria cutanea tarda.

Download full-text PDF

Source
http://dx.doi.org/10.2165/00002018-199614040-00005DOI Listing

Publication Analysis

Top Keywords

photosensitivity
9
antipsychotics antidepressants
8
photosensitivity induced
8
induced exogenous
8
porphyria cutanea
8
cutanea tarda
8
photosensitivity systemic
8
photosensitivity associated
4
associated antipsychotics
4
antidepressants anxiolytics
4

Similar Publications

Photodynamic therapy (PDT) holds promise as a cancer treatment modality due to its potential for enhanced therapy precision and safety. To enhance deep tissue penetration and minimize tissue adsorption and phototoxicity, developing photosensitizers activated by second near-infrared window (NIR-II) light shows significant potential. However, the efficacy of PDT is often impeded by tumor microenvironment hypoxia, primarily caused by irregular tumor vasculature.

View Article and Find Full Text PDF

The hypoxic environment of solid tumors significantly diminishes the therapeutic efficacy of oxygen-dependent photodynamic therapy. Developing efficient photosensitizers that operate photoredox catalysis presents a promising strategy to overcome this challenge. Herein, we report the rational design of two rhenium(I) tricarbonyl complexes ( and ) with electron donor-acceptor-donor configuration.

View Article and Find Full Text PDF

Expanding the spectral response of photocatalysts to facilitate overall water splitting (OWS) represents an effective approach for improving solar spectrum utilization efficiency. However, the majority of single-phase photocatalysts designed for OWS primarily respond to the ultraviolet region, which accounts for a small proportion of sunlight. Herein, we present a versatile strategy to achieve broad visible-light-responsive OWS photocatalysis dominated by direct ligand-to-cluster charge transfer (LCCT) within metal-organic frameworks (MOFs).

View Article and Find Full Text PDF

Nutraceuticals are not regulated by the US Food and Drug Administration, so a careful literature review is essential to make clinical decisions. Riboflavin or vitamin B2 can be recommended for migraine prevention in adults, but pediatric use is not proven. Adverse events are minimal.

View Article and Find Full Text PDF

Background: Current treatment strategies for hormone-dependent breast cancers, including adjuvant endocrine therapy, often fail due to persistence of breast cancer stem cells (brCSCs), which are significant contributors to tumor recurrence and treatment resistance. Therefore, gaining deeper insights into the molecular regulators driving breast cancer aggressiveness is important. Moreover, given the complexities and expenses involved in developing new pharmacological agents, the strategic repurposing of existing FDA-approved drugs to target these key molecular pathways presents a compelling approach for identifying novel therapeutic interventions aimed at mitigating tumor refractoriness.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!